Australia, 19th Nov 2025 – Neuralia TMS, a respected provider of neuromodulation treatments in Melbourne’s inner north, has reaffirmed its commitment to delivering evidence-supported Transcranial Magnetic Stimulation (TMS) therapy for individuals experiencing treatment-resistant depression. The clinic, located at Suite 102/149-155 Pascoe Vale Rd, Moonee Ponds 3039 VIC, continues to operate as a treatment centre offering structured, non-invasive therapeutic programs grounded in current clinical research.

TMS therapy has become an established component of modern mental health treatment in Australia, offering an option for individuals for whom conventional interventions have not produced sufficient improvement. The technique uses externally applied magnetic pulses to stimulate specific brain regions involved in mood regulation. This non-invasive approach allows treatment to occur without the use of medication, anaesthesia or surgical procedures, making it suitable for use within regulated outpatient clinical settings such as Neuralia TMS.

The clinic’s treatment framework reflects the broader movement within mental health care toward diversified therapeutic pathways. Depression represents a complex condition influenced by biological and psychosocial elements, and treatment plans frequently draw on multiple modalities. TMS therapy has become increasingly integrated into multidisciplinary care, supported by published research and an expanding body of clinical experience. Neuralia TMS incorporates this modality within a structured protocol designed to support consistency, safety and adherence to established standards.

Dr Shanek Wick, Medical Director at Neuralia TMS, highlighted the clinical importance of offering regulated neuromodulation within the community. “TMS therapy at Neuralia TMS provides an evidence-supported method for addressing depressive symptoms when traditional treatment avenues have presented limitations,” Dr Wick stated. “The structured application of neuromodulation reflects developments in mental health care that place emphasis on targeted, measurable interventions.”

Treatment programs at Neuralia TMS generally involve repeated sessions across several weeks, with each appointment undertaken by trained clinical team members familiar with TMS operational procedures. Session duration, treatment frequency and stimulation parameters adhere to recognised guidelines, ensuring that each course of therapy aligns with contemporary clinical recommendations. Thorough monitoring supports continuity and allows clinicians to observe patient response within a controlled framework.

In addition to TMS therapy, Neuralia TMS delivers supplementary services that contribute to broader treatment planning. Transcranial Direct Current Stimulation (tDCS) is available as an at-home neuromodulation option for individuals for whom ongoing structured support is clinically appropriate. The clinic also offers pharmacogenetic testing, which provides clinicians with information regarding potential medication responsiveness based on genetic markers. These tools assist in building a more informed treatment plan and serve as adjuncts to professional assessment.

The expansion of neuromodulation within Australian mental health care reflects increasing interest in treatment options beyond medication alone. Research examining TMS continues to explore its potential relevance across a range of conditions, including anxiety disorders, PTSD, OCD, chronic pain and neurological conditions such as Parkinson’s disease. Neuralia TMS aligns its operational standards with current research findings and professional guidelines to ensure that treatment delivery remains consistent with evidence-supported practice.

Mental health treatment continues to evolve as new technologies and scientific insights become available. Depression, in particular, remains a leading contributor to health-related disability, creating an ongoing need for therapeutic diversity. TMS therapy functions as one of several components within broader treatment planning, supporting individuals whose circumstances require an alternative approach to traditional interventions.

Looking to the future, Dr Wick noted the significance of continuing advances in the field. “Research into neuromodulation continues to progress, revealing emerging applications and refining existing methodologies,” Dr Wick said. “Ongoing developments are expected to enhance precision, broaden accessibility and strengthen the integration of neuromodulation within mental health care.”

Neuralia TMS maintains a focus on delivering regulated neuromodulation services that align with contemporary evidence. Through ongoing refinement of treatment protocols, continued engagement with research and an emphasis on clinical oversight, the clinic aims to contribute meaningfully to the evolving landscape of mental health treatment in Australia. The organisation’s structured approach reflects broader sector-wide efforts to improve outcomes for individuals experiencing depression and related conditions.

For further information about TMS for depression, Neuralia TMS can be contacted on 03 9122 5246 or via email at info@neuralia.com.au. The clinic is located at Suite 102/149-155 Pascoe Vale Rd, Moonee Ponds 3039 VIC.

Media Contact

Organization: Neuralia TMS (Melbourne)

Contact Person: Dr Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email

Contact Number: +61391225246

Address:102/ 149-155 Pascoe Vale Rd

Address 2: Moonee Ponds Vic 3039

Country:Australia

Release id:37317

Disclaimer: This information is provided for general informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare professional for guidance specific to their circumstances.

The post Neuralia TMS Provides Proven TMS Therapy to Help Manage Depression appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Boca Raton, FL, United States, 19th Nov 2025 – Entero Therapeutics, Inc. (“Entero”) today announced that its wholly owned subsidiary, Grid AI, is finalizing the formation of a U.S.-based executive leadership team as the company accelerates its expansion into the rapidly scaling domestic market for AI-ready digital infrastructure and orchestration technologies.

Grid AI expects to announce the appointment of a U.S.-based Chief Executive Officer and Executive Chairman in the near term. The incoming leaders are seasoned public-market operators with extensive experience building and scaling global companies in the demand-response, energy-flexibility, and digital-infrastructure sectors. Their backgrounds align directly with Grid AI’s mission to deliver integrated AI orchestration, energy-optimization, and intelligent infrastructure-control solutions for hyperscale and enterprise AI deployments.

The leadership expansion comes at a critical moment for the global compute and data-center ecosystem. This week, AMD CEO Dr. Lisa Su forecast that the global data-center market could reach $1 trillion by 2030, driven by unprecedented AI-compute demand. Supporting that growth could require more than 2,000 new data centers worldwide, each needing advanced AI-driven control systems, power orchestration, and real-time energy market optimization—the core capabilities of the Grid AI platform.

“With more than $50 million invested since 2019 to develop, test, and commercialize this autonomous platform, Grid AI is entering a new phase,” said Jason Sawyer, CEO of Entero. “Building a dedicated U.S. leadership team enhances our execution capabilities and strengthens our ability to support large-scale AI-driven SaaS deployments across the domestic digital-infrastructure landscape.”

Grid AI plans to provide further updates on leadership appointments, commercial initiatives, and its broader U.S. expansion strategy in the coming weeks.

The company’s U.S. buildout supports Entero’s long-term objective to capture value at the intersection of artificial intelligence, energy systems, and next-generation digital infrastructure.

About Entero Therapeutics, Inc.

Entero Therapeutics, Inc. is a technology company focused on solutions at the intersection of artificial intelligence, energy systems, and digital infrastructure. The company was founded in 2019 and operates through its wholly owned subsidiary, Grid AI. Entero is headquartered in the United States

Media Contact

Organization: Entero Investor Relations

Contact Person: Jason Sawyer

Website: https://enterothera.com/

Email:
investors@enterothera.com

Address:BOCA RATON, FL

City: Boca Raton

State: FL

Country:United States

Release id:37236

The post Entero’s Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure Strategy appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Grand Shanghai Restaurant was recognized as a leading Chinese wedding venue in Singapore, based on a survey of 100 couples who celebrated their weddings during 2024 and 2025.

Singapore, 19th Nov 2025 – Grand Shanghai Restaurant was recognized as a leading Chinese wedding venue in Singapore, based on a survey of 100 couples who celebrated their weddings during 2024 and 2025.

Now marking its 25th anniversary, the distinguished establishment received exceptional ratings for its genuine Shanghainese cuisine, sophisticated ambiance, and all-inclusive wedding packages that seamlessly blend restaurant-quality dining with hotel-level conveniences.

Situated in Kings Centre just minutes from Havelock MRT Station, Grand Shanghai has firmly established itself as the destination of choice for couples seeking a perfect balance of traditional Chinese elegance and contemporary luxury for their wedding celebrations.

What Sets Grand Shanghai Apart

The survey highlighted several key factors that elevate Grand Shanghai above other wedding venues:

• Exceptional Culinary Experience: Newlyweds commended the authentic Shanghainese cuisine, with consistent pricing for both lunch and dinner receptions.
• Versatile Capacity Options: The venue easily accommodates celebrations ranging from intimate gatherings of 150 to larger affairs with up to 250 attendees.
• Complete Wedding Solutions: Through a partnership with renowned Annabel Law Productions, comprehensive packages include professional photography, videography, floral arrangements, personalized invitations, and complimentary hotel accommodations.
• Convenient Location: Couples appreciated the venue’s accessibility, with its proximity to public transportation and ample parking at Kings Centre.
• Distinctive Decor: The Oriental-inspired setting featuring a striking 2.5-meter double happiness backdrop and elegant floral installations received particular praise.

Premium inclusions in their wedding packages feature a complimentary hotel stay, selected beverages, and 20% parking discounts for guests.

For couples with diverse dietary needs, Grand Shanghai offers vegetarian and No Pork No Lard (Muslim-friendly) menu options at the same competitive price point, ensuring an inclusive celebration for all guests.

Media Contact

Organization: Wedding Venue Singapore

Contact Person: Annabel Law

Website: https://www.weddingvenue.sg

Email: Send Email

Address:133 DEVONSHIRE ROAD

Address 2: #01-01

Country:Singapore

Release id:37017

The post Grand Shanghai Restaurant Recognized in Wedding Venue Singapore Survey of Top Chinese Wedding Venues appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section